Medical Condition

bladder cancer

Total Trials

19

Recruiting Now

19

Trial Phases

Phase 2, Phase 1, Phase 2, Phase 1

Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.

Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.

The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.

Frequently Asked Questions — bladder cancer Clinical Trials

How many clinical trials are currently recruiting for bladder cancer?

ClinicalMetric currently tracks 19 actively recruiting clinical trials for bladder cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 19. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for bladder cancer?

bladder cancer research spans Phase 1 (4 trials), Phase 2 (3 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a bladder cancer clinical trial?

Eligibility criteria for bladder cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Istituto Clinico Humanitas 1 trial

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1 trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 1 trial

Essen Biotech 1 trial

Regina Elena Cancer Institute 1 trial

bladder cancer

Frequently Asked Questions — bladder cancer Clinical Trials

Recruiting Clinical Trials

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Renal Retention in High Grade Upper Tract Urothelial Cancer

Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Urinary Microbiome Differences in Bladder Cancer, Benign Urinary Diseases and Healthy Counterparts in Adult Male Population

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?

IDOV-Immune for Advanced Solid Tumors

Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

A Study of Surgical Techniques During Cystectomy

Predicting BCG Response